UREX GR-1 plus RC-14,
does it really help with Growth of beneficial vaginal bacteria and reduction of bacterial-vaginosis recurrence?
research showsSmall RCTs adding oral GR-1 plus RC-14 to antibiotics reported better 30-day bacterial-vaginosis cure and vaginal flora, but a larger Chinese cohort RCT found no benefit in 30- or 90-day cure or vaginal and fecal microbiota. The evidence is strain-specific, adjunctive, and conflicting and does not directly confirm long-term recurrence prevention, so the grade is C.
ads claimClaims that oral strains 'travel from the gut to the vagina,' 'prevent vaginitis,' or 'block recurrence' expand strain detection and short-term treatment-adjunct findings into long-term prevention in healthy women. Individual regulatory recognition documents trials and specifications, not definitive treatment efficacy.
Useful facts when choosing a product
- The individually recognized UREX ingredient in South Korea specifies a combined 1 billion CFU/day of GR-1 and RC-14, and relevant finished products are commonly sold as one capsule daily.
- Evidence is limited to the exact two strains and specific doses; other strains of the same Lactobacillus species are not substitutes.
- Major positive trials added probiotics during antibiotic treatment of bacterial vaginosis, which differs from standalone preventive use.
What the research actually shows
Anukam 2006 randomized 125 women with bacterial vaginosis to oral metronidazole plus GR-1 and RC-14 or placebo and reported 30-day cure of 88% versus 40%. Martinez 2009 added four weeks of probiotics to single-dose tinidazole and reported 80% versus 50% cure. In contrast, Zhang 2021 studied 126 women and found no significant benefit after vaginal metronidazole: 59.6% versus 57.7% cure at day 30 and 48.9% versus 36.5% at day 90, with no demonstrated vaginal engraftment from oral dosing. A 14-day postmenopausal trial used the Nugent score as a surrogate.
Why this is classified as C (50)
Direct RCTs exist, but small positive adjunctive trials conflict with a larger null trial and recurrence evidence is weak, resulting in C with 57 points.
Counterpoint. A short-term adjunctive benefit during antibiotic therapy remains possible, but this does not replace standard treatment.
Rejudgment record. New verdict — Strain-specific RCTs exist, but small positive antibiotic-adjunct trials conflict with a larger null trial and long-term recurrence endpoints are insufficient
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Growth of beneficial vaginal bacteria | C | Some Nugent-score improvement was reported, but the larger trial did not confirm vaginal engraftment after oral dosing. |
| Reduction of bacterial-vaginosis recurrence | C | Major positive trials measured 30-day cure, while 90-day results were null, so long-term recurrence reduction is unconfirmed. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Anukam K et al. 2006 | Randomized, double-blind, placebo-controlled adjunctive trial | 106 | Probiotic product support and investigator links to the strains | Thirty-day cure and Nugent score with metronidazole | Cure was 88% versus 40%; this was a short-term antibiotic-adjunct result. | Key |
| Martinez RCR et al. 2009 | Randomized, double-blind, placebo-controlled adjunctive trial | 64 | Product and strain-linked support | Four-week cure and flora with tinidazole | Cure was 80% versus 50% in a small, short adjunctive trial. | Key |
| Zhang Y et al. 2021 | Prospective, parallel-group randomized controlled trial | 126 | Academic research with product supply | Thirty- and ninety-day cure plus vaginal and fecal microbiota | No difference in cure at day 30 or 90 and no vaginal engraftment benefit after oral dosing. | Key and conflicting |
| Petricevic L et al. 2008 | Randomized, double-blind, placebo-controlled trial | 72 | Product-related support | Fourteen-day Nugent vaginal-flora score | Vaginal-flora score improved; this was a short-term surrogate rather than clinical recurrence. | Supportive |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-17).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none
Cite this verdict
[Chamgap] UREX GR-1 plus RC-14 x beneficial vaginal bacteria and bacterial-vaginosis recurrence — Evidence Grade C·50. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/urex-gr1-rc14-vaginal-flora-bv/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.